Display options
Cite
Blázquez B, Fresco-Taboada A, Iglesias-Bexiga M, et al. PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species. Front Microbiol. 2016;7:1156doi: 10.3389/fmicb.2016.01156.
Blázquez, B., Fresco-Taboada, A., Iglesias-Bexiga, M., Menéndez, M., & García, P. (2016). PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species. Frontiers in microbiology, 71156. https://doi.org/10.3389/fmicb.2016.01156
Blázquez, Blas, et al. "PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species." Frontiers in microbiology vol. 7 (2016): 1156. doi: https://doi.org/10.3389/fmicb.2016.01156
Blázquez B, Fresco-Taboada A, Iglesias-Bexiga M, Menéndez M, García P. PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species. Front Microbiol. 2016 Jul 28;7:1156. doi: 10.3389/fmicb.2016.01156. eCollection 2016. PMID: 27516758; PMCID: PMC4963390.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 Jul 28;7:1156. doi: 10.3389/fmicb.2016.01156. eCollection 2016.

PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species.

Frontiers in microbiology

Blas Blázquez, Alba Fresco-Taboada, Manuel Iglesias-Bexiga, Margarita Menéndez, Pedro García

Affiliations

  1. Departamento de Microbiología Molecular y Biología de las Infecciones, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas Madrid, Spain.
  2. Departamento de Química-Física Biológica, Instituto Química-Física Rocasolano, Consejo Superior de Investigaciones CientíficasMadrid, Spain; CIBER de Enfermedades RespiratoriasMadrid, Spain.
  3. Departamento de Microbiología Molecular y Biología de las Infecciones, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones CientíficasMadrid, Spain; CIBER de Enfermedades RespiratoriasMadrid, Spain.

PMID: 27516758 PMCID: PMC4963390 DOI: 10.3389/fmicb.2016.01156

Abstract

The emergence and spread of antibiotic-resistant bacteria is pushing the need of alternative treatments. In this context, phage therapy is already a reality to successfully fight certain multiresistant bacteria. Among different phage gene products, murein hydrolases responsible of phage progeny liberation (also called lysins or endolysins) are weapons that target specific peptidoglycan bonds, leading to lysis and death of susceptible bacteria when added from the outside. In the pneumococcal system, all but one phage murein hydrolases reported to date share a choline-binding domain that recognizes cell walls containing choline residues in the (lipo)teichoic acids. Some purified pneumococcal or phage murein hydrolases, as well as several chimeric proteins combining natural catalytic and cell wall-binding domains (CBDs) have been used as effective antimicrobials. In this work we have constructed a novel chimeric N-acetylmuramoyl-L-alanine amidase (PL3) by fusing the catalytic domain of the Pal amidase (a phage-coded endolysin) to the CBD of the LytA amidase, the major pneumococcal autolysin. The physicochemical properties of PL3 and the bacteriolytic effect against several pneumococci (including 48 multiresistant representative strain) and related species, like Streptococcus pseudopneumoniae, Streptococcus mitis, and Streptococcus oralis, have been studied. Results have shown that low doses of PL3, in the range of 0.5-5 μg/ml, are enough to practically sterilize all choline-containing strains tested. Moreover, a single 20-μg dose of PL3 fully protected zebrafish embryos from infection by S. pneumoniae D39 strain. Importantly, PL3 keeps 95% enzymatic activity after 4 weeks at 37°C and can be lyophilized without losing activity, demonstrating a remarkable robustness. Such stability, together with a prominent efficacy against a narrow spectrum of human pathogens, confers to PL3 the characteristic to be an effective therapeutic. In addition, our results demonstrate that the structure/function-based domain shuffling approach is a successful method to construct tailor-made endolysins with higher bactericidal activities than their parental enzymes.

Keywords: Streptococcus mitis; Streptococcus oralis; Streptococcus pseudopneumoniae; chimeric protein; lysin; phage therapy; pneumococcus

References

  1. Nat Struct Biol. 2001 Dec;8(12):1020-4 - PubMed
  2. Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91 - PubMed
  3. Antimicrob Agents Chemother. 2013 Jun;57(6):2743-50 - PubMed
  4. Trends Biochem Sci. 2003 May;28(5):230-4 - PubMed
  5. J Appl Microbiol. 2015 Sep;119(3):620-31 - PubMed
  6. J Am Soc Mass Spectrom. 2008 Jul;19(7):927-37 - PubMed
  7. J Antimicrob Chemother. 2015;70(6):1763-73 - PubMed
  8. J Biol Chem. 1976 Jul 25;251(14):4199-207 - PubMed
  9. Antimicrob Agents Chemother. 2007 Sep;51(9):3371-3 - PubMed
  10. Science. 2001 Dec 7;294(5549):2170-2 - PubMed
  11. J Biol Chem. 2010 Oct 22;285(43):33184-96 - PubMed
  12. J Antimicrob Chemother. 2006 May;57(5):819-24 - PubMed
  13. J Med Microbiol. 2013 Oct;62(Pt 10):1506-16 - PubMed
  14. Clin Infect Dis. 2002 Jun 1;34(11):1524-9 - PubMed
  15. Mol Microbiol. 1997 Aug;25(4):717-25 - PubMed
  16. J Biol Chem. 2011 Sep 30;286(39):34391-403 - PubMed
  17. J Biol Chem. 1996 Nov 15;271(46):29152-61 - PubMed
  18. J Bacteriol. 2007 Jan;189(1):38-51 - PubMed
  19. J Biol Chem. 2004 Oct 15;279(42):43697-707 - PubMed
  20. J Bacteriol. 2004 Jul;186(14):4808-12 - PubMed
  21. Am J Respir Crit Care Med. 2015 Jan 15;191(2):135-40 - PubMed
  22. Eur J Biochem. 1990 Jan 26;187(2):409-16 - PubMed
  23. Environ Microbiol Rep. 2011 Dec;3(6):640-50 - PubMed
  24. Biochim Biophys Acta. 1960 Apr 22;39:508-18 - PubMed
  25. J Biol Chem. 1996 Mar 22;271(12):6832-8 - PubMed
  26. J Gen Microbiol. 1983 Feb;129(2):489-97 - PubMed
  27. Appl Environ Microbiol. 2006 Apr;72(4):2988-96 - PubMed
  28. Antimicrob Agents Chemother. 2011 Feb;55(2):738-44 - PubMed
  29. Emerg Infect Dis. 2014 May;20(5):762-71 - PubMed
  30. J Biol Chem. 1970 Jan 25;245(2):287-98 - PubMed
  31. Lancet Infect Dis. 2016 Feb;16(2):239-51 - PubMed
  32. Curr Opin Microbiol. 2007 Oct;10(5):461-72 - PubMed
  33. Biophys J. 2006 Jun 15;90(12):4651-61 - PubMed
  34. J Infect Dis. 2007 Oct 15;196(8):1237-47 - PubMed
  35. Infect Immun. 2013 Mar;81(3):753-63 - PubMed
  36. Microbiology. 2009 Jul;155(Pt 7):2223-34 - PubMed
  37. Environ Microbiol. 2009 Oct;11(10):2542-55 - PubMed
  38. Mol Oral Microbiol. 2011 Apr;26(2):89-98 - PubMed
  39. Clin Microbiol Rev. 2016 Jul;29(3):525-52 - PubMed
  40. Lancet. 2013 Apr 20;381(9875):1405-16 - PubMed
  41. Adv Virus Res. 2012;83:299-365 - PubMed
  42. J Bacteriol. 2001 Oct;183(19):5709-17 - PubMed
  43. Antimicrob Agents Chemother. 2012 Aug;56(8):4504-7 - PubMed
  44. Sci Rep. 2015 Nov 26;5:17257 - PubMed
  45. Acta Crystallogr D Biol Crystallogr. 2015 Jun;71(Pt 6):1373-81 - PubMed
  46. J Biol Chem. 2000 Sep 1;275(35):26842-55 - PubMed
  47. Antimicrob Resist Infect Control. 2013 Nov 18;2:31 - PubMed
  48. J Antimicrob Chemother. 2008 Dec;62(6):1234-40 - PubMed
  49. MBio. 2014 Feb 11;5(1):e01120-13 - PubMed
  50. J Bacteriol. 2006 Nov;188(22):7785-95 - PubMed
  51. Eur J Biochem. 2003 May;270(10):2157-62 - PubMed
  52. Antimicrob Agents Chemother. 2013 Nov;57(11):5355-65 - PubMed
  53. Antimicrob Agents Chemother. 2010 Apr;54(4):1603-12 - PubMed
  54. J Antimicrob Chemother. 2003 Dec;52(6):967-73 - PubMed

Publication Types